Opinion statement
Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor—the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Norton JA. Adrenal tumors. In Cancer: Principles and Practice of Oncology edn 5. Edited by DeVita V, Hellman S, Rosenberg D. Philadelphia: Lippincott-Raven Publishers, 1997:1659.
Wooten MD, King DK: Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993, 72:3145–3155.
Icard P, Chapuis Y, Andreassian B, et al.:Adrenal cortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French association of endocrine surgery. Surgery 1992, 112:972–979.
Lee JE, Evans DB, Hickey RC, et al.: Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 1998, 124:1115–1122. Paper from a center experienced in the management of patients with adrenal cortical cancer and adrenal masses.
Ross NS, Aron DC: Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990, 323:1401–1405.
Doppman JL, Reinig JW, Dwyer AJ, et al.: Differentiation of adrenal masses by magnetic resonance imaging. Surgery 1987, 102:1018–1026.
Schell SR, Talamini MA, Udelsman R: Laparoscopic adrenalectomy for nonmalignant disease: improved safety, morbidity, and cost-effectiveness. Surg Endosc 1999, 13:30–34.
Kopf D, Goretzki PE, Lehnert H: Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001, 127:143–155. Recent review of adrenal tumor management.
Haak HR, Hermans J, van de Velde CJ, et al.: Optimal treatment of adrenal cortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994, 69:947–951.
Luton JP, Cerdas S, Billaud L, et al.: Clinical features of adrenal cortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322:1195–1201.
Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al.: Impact of adjuvant mitotane on the clinical course of patients with adrenal cortical cancer. Cancer 1993, 71:3119–3123.
Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, et al.: Adrenal cortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995, 75:2587–2591.
Bonacci R, Gigliotti A, Baudin E, et al.: Cytotoxic therapy with etoposide and cisplatin in advanced adrenal cortical carcinoma. Reseau comete inserm. Br J Cancer 1998, 78:546–549.
Schlumberger M, Gicquel C, Lumbroso J, et al.: Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992, 15:631–642.
Bates SE, Shieh CY, Mickley LA, et al.: Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/p-glycoprotein) which is also expressed by adrenal cortical carcinomas. J Clin Endocrinol Metab 1991, 73:18–29.
Berruti A, Terzolo M, Paccotti P, et al.: Favorable response of metastatic adrenal cortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases. Tumori 1992, 78:345–348.
Chan NN, Isaacs AJ: Lack of response to octreotide in Cushing’s syndrome due to metastatic adrenal cortical carcinoma. Postgrad Med J 1999, 75:96–97.
Arlt W, Reincke M, Siekmann L, et al.: Suramin in adrenal cortical cancer: Limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 1994, 41:299–307.
Wu YW, Chik CL, Knazek RA: An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenal cortical carcinoma. Cancer Res 1989, 49:3754–3758.
Fallo F, Pilon C, Barzon L, et al.: Effects of taxol on the human NCI-H295 adrenal cortical carcinoma cell line. Endocrinol Res 1996, 22:709–715.
Engelhardt D, Weber MM: Therapy of Cushing’s syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 1994, 49:261–267.
Thoren M, Adamson U, Sjoberg HE: Aminoglutethimide and metyrapone in the management of Cushing’s syndrome. Acta Endocrinol (Copenh) 1985, 109:451–457.
Harrison|LE, Gaudin PB, Brennan MF: Pathologic features of prognostic significance for adrenal cortical carcinoma after curative resection. Arch Surg 1999, 134:181–185. Tumor diameter greater than 12 cm, six or more mitotic figures per 10 high-power fields, and the presence of histologic evidence of intratumoral hemorrhage were found to predict short survival in this series of patients from another experienced center.
Khorram-Manesh A, Ahlman H, Jansson S, et al.: Adrenal cortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998, 22:605–611.
Crucitti F, Bellantone R, Ferrante A, et al.: The Italian registry for adrenal cortical carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996, 119:161–170.
Lee|JE, Berger DH, el-Naggar AK, et al.: Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995, 118:1090–1098. This paper emphasizes the importance of marginnegative resection in the management of patients with adrenal cortical carcinoma.
Zografos GC, Driscoll DL, Karakousis CP, et al.: Adrenal adenocarcinoma: a review of 53 cases. J Surg Oncol 1994, 55:160–164.
Icard P, Louvel A, Chapuis Y: Survival rates and prognostic factors in adrenal cortical carcinoma. World J Surg 1992, 16:753–758.
Pommier RF, Brennan MF: An eleven-year experience with adrenal cortical carcinoma. Surgery 1992, 112:963–970.
Soreide JA, Brabrand K, Thoresen SO: Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg 1992, 16:663–667.
Gröndal S, Cedermark B, Eriksson B, et al.: Adrenal cortical carcinoma. A retrospective study of a rare tumor with a poor prognosis. Eur J Surg Oncol 1990, 16:500–506.
Henley DJ, van Heerden JA, Grant CS, et al.: Adrenal cortical carcinoma—a continuing challenge. Surgery 1983, 94:926–931.
Sullivan M, Boileau M, Hodges CV: Adrenal cortical carcinoma. J Urol 1978, 120:660–665.
MacFarlane DA: Cancer of the adrenal cortex. The natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958, 23:155–186.
Venkatesh S, Hickey RC, Sellin RV, et al.: Adrenal cortical carcinoma. Cancer 1989, 64:765–769.
Karakousis CP, Rao U, Moore R: Adrenal adenocarcinomas: histologic grading and survival. J Surg Oncol 1985, 29:105–111.
van Slooten H, Moolenaar AJ, van Seters AP, et al.: The treatment of adrenal cortical carcinoma with o,p’-ddd: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984, 20:47–53.
Abraham S, Bakke A, Rutt B, et al.: A study of combination chemotherapy and surgical resection in the treatment of adrenal cortical cancer (ACC): continuous infusion doxorubicin, vincristine and etoposide with daily mitotane before and after surgical resection. Proc Am Soc Clin Oncol 1999, 18:191a.
Berruti A, Terzolo M, Pia A, et al.: Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenal cortical carcinoma. Italian group for the study of adrenal cancer. Cancer 1998, 83:2194–2200.
Zidan J, Shpendler M, Robinson E: Treatment of metastatic adrenal cortical carcinoma with etoposide (VP-16) and cisplatin after failure with o,p’ddd. Clinical case reports. Am J Clin Oncol 1996, 19:229–231.
Bukowski RM, Wolfe M, Levine HS, et al.: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group Study. J Clin Oncol 1993, 11:161–165.
Hesketh PJ, McCaffrey RP, Finkel HE, et al.: Cisplatinbased treatment of adrenal cortical carcinoma. Cancer Treat Rep 1987, 71:222–224.
Johnson DH, Greco FA: Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer 1986, 58:2198–2202.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boushey, R.P., Dackiw, A.P.B. Adrenal cortical carcinoma. Curr. Treat. Options in Oncol. 2, 355–364 (2001). https://doi.org/10.1007/s11864-001-0029-1
Issue Date:
DOI: https://doi.org/10.1007/s11864-001-0029-1